INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 346 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,540,840 | -44.6% | 681,241 | -28.5% | 0.01% | -45.5% |
| Q2 2023 | $38,851,799 | +19.9% | 952,717 | +9.6% | 0.01% | +10.0% |
| Q1 2023 | $32,394,041 | +4.0% | 869,172 | -2.6% | 0.01% | 0.0% |
| Q4 2022 | $31,143,895 | -27.9% | 892,631 | +15.6% | 0.01% | -33.3% |
| Q3 2022 | $43,200,000 | +17.0% | 771,975 | +8.2% | 0.02% | +15.4% |
| Q2 2022 | $36,928,000 | -27.0% | 713,445 | +2.5% | 0.01% | -13.3% |
| Q1 2022 | $50,605,000 | -37.2% | 696,367 | +2.1% | 0.02% | -37.5% |
| Q4 2021 | $80,631,000 | -9.9% | 681,921 | +2.3% | 0.02% | -17.2% |
| Q3 2021 | $89,455,000 | +20.8% | 666,822 | +45.8% | 0.03% | +16.0% |
| Q2 2021 | $74,041,000 | +113.9% | 457,297 | +6.0% | 0.02% | +92.3% |
| Q1 2021 | $34,608,000 | +71.7% | 431,216 | +16.4% | 0.01% | +62.5% |
| Q4 2020 | $20,152,000 | +196.6% | 370,433 | +8.4% | 0.01% | +166.7% |
| Q3 2020 | $6,794,000 | +7.4% | 341,742 | +13.6% | 0.00% | 0.0% |
| Q2 2020 | $6,323,000 | +109.4% | 300,805 | +21.8% | 0.00% | +50.0% |
| Q1 2020 | $3,020,000 | -15.7% | 246,878 | +1.1% | 0.00% | 0.0% |
| Q4 2019 | $3,583,000 | +12.5% | 244,195 | +2.4% | 0.00% | 0.0% |
| Q3 2019 | $3,184,000 | -0.9% | 238,500 | +21.6% | 0.00% | 0.0% |
| Q2 2019 | $3,212,000 | +2.8% | 196,210 | +7.2% | 0.00% | 0.0% |
| Q1 2019 | $3,126,000 | +33.4% | 183,005 | +6.6% | 0.00% | 0.0% |
| Q4 2018 | $2,343,000 | -52.9% | 171,618 | -1.2% | 0.00% | -33.3% |
| Q3 2018 | $4,974,000 | +39.7% | 173,762 | +33.6% | 0.00% | 0.0% |
| Q2 2018 | $3,560,000 | +84.6% | 130,108 | +42.4% | 0.00% | +200.0% |
| Q1 2018 | $1,928,000 | +26.8% | 91,385 | +15.5% | 0.00% | 0.0% |
| Q4 2017 | $1,521,000 | +6.4% | 79,129 | +37.6% | 0.00% | 0.0% |
| Q3 2017 | $1,429,000 | +109.2% | 57,492 | +34.7% | 0.00% | 0.0% |
| Q2 2017 | $683,000 | +79.7% | 42,674 | +58.6% | 0.00% | – |
| Q1 2017 | $380,000 | +14.1% | 26,903 | +6.1% | 0.00% | – |
| Q4 2016 | $333,000 | -18.6% | 25,364 | +5.8% | 0.00% | – |
| Q3 2016 | $409,000 | -15.8% | 23,978 | +5.4% | 0.00% | -100.0% |
| Q2 2016 | $486,000 | – | 22,754 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |